Community Practice Connections™: Medical Crossfire®: How Are We Integrating New Treatment Strategies Into the Care of Our B-Cell Lymphoma Patients?

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Genmab USA, Inc., Incyte Corporation, Janssen Biotech, Inc., Pharmacyclics, an AbbVie Company and TG Therapeutics, Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain diagnostic and prognostic biomarkers underlying treatment decisions for marginal-zone lymphoma (MZL), follicular lymphoma (FL), and mantle-cell lymphoma (MCL).
• Evaluate safety and efficacy profiles for evolving therapeutic options to treat MZL, FL, and MCL.
• Integrate practice-changing data and evidence-based recommendations into personalized treatment plans for patients with MZL, FL, and MCL, including strategies to monitor and mitigate therapy-related adverse events.
• Assess recent clinical trial results and ongoing trials evaluating novel agents used alone or in combination to treat patients with MZL, FL, and MCL.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities
 

Faculty

Philippe Armand, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Lymphoma
Harold and Virginia Lash Endowed Chair in Lymphoma Research
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Merck & Co., Inc.; Bristol Myers Squibb; Affimed GmbH; Adaptive Biotechnologies; F. Hoffmann-La Roche AG; Genentech, Inc.; IGM Biosciences; Kite Pharma; Consultant: Merck & Co., Inc.; Bristol Myers Squibb; Pfizer; Affimed GmbH; Adaptive Biotechnologies; Infinity Pharmaceuticals; ADC Therapeutics; Celgene Corporation; MorphoSys AG; Daiichi Sankyo Company Ltd; Miltenyi Biotec Inc.; Tessa Therapeutics; GenMab Inc; C4 Therapeutics; Enterome; Regeneron Pharmaceuticals, Inc.; Epizyme, Inc.; AstraZeneca; Genentech, Inc.; Other: Honoraria: Bristol Myers Squibb; Merck & Co., Inc.

Loretta J. Nastoupil, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Lymphoma Outcomes Database
Section Chief, Indolent Lymphoma and New Drug Development
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: Bristol Myers Squibb/Celgene; Caribou Biosciences; Epizyme, Inc.; Genentech, Inc.; IGM Biosciences; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis; TG Therapeutics; Takeda Oncology; Consultant: ADC Therapeutics; Bayer; Bristol Myers Squibb/Celgene; Genentech, Inc.; Gilead Sciences/Kite Pharma; Janssen Pharmaceuticals; MorphoSys AG; Novartis; TG Therapeutics; Takeda Oncology.

Jason Westin, MD, MS, FACP
Associate Professor, Department of Lymphoma/Myeloma
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: Kite Pharma; Novartis; Bristol Myers Squibb; Janssen Pharmaceuticals; Genentech, Inc.; Unum Therapeutics; Forty Seven Inc.; AstraZeneca; MorphoSys AG; Curis, Inc.; Consultant: Kite Pharma; Novartis, Bristol Myers Squibb; Janssen Pharmaceuticals; Genentech, Inc.; AstraZeneca; MorphoSys AG; Curis, Inc.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.